Track AUPH and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Aurinia Pharmaceuticals Inc
#140, 14315 ? 118 Avenue, Edmonton, AB, Canada, T5L 4S6
IPO
1999
Employees
128
Industry
Biotechnology
Sector
Healthcare
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20260+1
1
Q3 20250+3
3
2-quarter cumulative
0 sells4 buys
Analyst Ratings
3 analysts covering
Buy67%recommend buy
Buy
2
Hold
1
Sell
0